De la nécessité des études coût-efficacité en ostéoporose. [The necessity of cost-effectiveness analysis in osteoporosis]

Détails

ID Serval
serval:BIB_01050A2EEDA3
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
De la nécessité des études coût-efficacité en ostéoporose. [The necessity of cost-effectiveness analysis in osteoporosis]
Périodique
Revue Médicale Suisse
Auteur(s)
Lamy O., Krieg M. A.
ISSN
1660-9379 (Print)
Statut éditorial
Publié
Date de publication
06/2007
Volume
3
Numéro
115
Pages
1521-5
Notes
English Abstract Journal Article --- Old month value: Jun 13
Résumé
Economic evaluations are increasingly being used by decision-makers to estimate the cost-effectiveness of interventions. Major changes have recently occurred in the treatment of osteoporosis. The development of a valid economic model (Markov) in the field of osteoporosis is discussed, as well as these limitations. Intervention, such hip protectors, calcium and vitamin D, bisphosphonates, hormonal replacement therapy, SERMs, strontium ranelate, analogue of parathyroid hormone are analysed in the light of cost-effectiveness analyses.
Mots-clé
Aged Aged, 80 and over Bone Density Conservation Agents/economics/therapeutic use Calcium/economics/therapeutic use Cost-Benefit Analysis Decision Making Diphosphonates/economics/therapeutic use Female Fractures, Bone/economics/prevention & control Health Care Costs Hip Fractures/economics/prevention & control Hormone Replacement Therapy/economics Humans Male Markov Chains Middle Aged Models, Economic Organometallic Compounds/economics/therapeutic use Osteoporosis/drug therapy/*economics Parathyroid Hormone/analogs & derivatives/economics Quality of Life Selective Estrogen Receptor Modulators/economics/therapeutic use Thiophenes/economics/therapeutic use Vitamin D/economics/therapeutic use
Pubmed
Création de la notice
25/01/2008 14:55
Dernière modification de la notice
03/03/2018 13:13
Données d'usage